Annals of internal medicine
-
Comparative Study
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts.
Allogeneic hematopoietic cell transplantation is indicated for refractory hematologic cancer and some nonmalignant disorders. Survival is limited by recurrent cancer and organ toxicity. ⋯ National Institutes of Health.
-
Editorial Comment
Taking Care Transitions Programs to Scale: Is the Evidence There Yet?